Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CCT301-59 in Recurrent/Refractory Solid Tumors
NCT03960060Phase 1Terminated
- Sponsor
- Shanghai PerHum Therapeutics
- Start
- May 2019
- Primary completion
- Jun 2022
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CCT301-59 in solid tumor, soft tissue sarcoma (STS), gastric cancer (GC) and 2 more, sponsored by Shanghai PerHum Therapeutics. Primary endpoints: Safety of CCT301-59 CAR T cell therapy up to 52 weeks, Efficacy of CCT301-59 CAR T cell therapy up to 52 weeks and 1 more. Started May 2019; status: terminated.
02
Drugs
CCT301-59
03
Conditions
solid tumorsoft tissue sarcoma (STS)gastric cancer (GC)pancreatic cancer (PC)bladder cancer
Beyond the preview
Go deeper on NCT03960060.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03960060.